文摘
To evaluate potential improvement in tissue specific targeting and cellular uptake of therapeuticribozymes, we have developed three new phosphoramidite reagents. These reagents can be used inautomated solid-phase synthesis to produce oligonucleotide conjugates containing N-acetyl-D-galactosamine (targeting hepatocytes) and folic acid (targeting tumor). N-Acetyl-D-galactosamine wasattached through a linker to both 2'-amino-2'-deoxyuridine and D-threoninol scaffolds, and theseconjugates were converted to phosphoramidite building blocks. Incorporation of a D-threoninol-basedmonomer into ribozymes provided multiply labeled ribozyme conjugates. Attachment of the fullyprotected pteroic acid to the D-threoninol-6-aminocaproyl-L-glutamic acid construct afforded the folicacid conjugate, which was converted into the phosphoramidite and incorporated onto the 5'-end ofthe ribozyme.